Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Feeling of body temperature change08.01.09.0120.000049%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Psychiatric symptom19.01.02.0010.000049%Not Available
Ill-defined disorder08.01.03.0490.000146%Not Available
Sensation of foreign body08.01.09.0020.000073%Not Available
Blood disorder01.05.01.0040.000049%Not Available
Lower limb fracture15.08.03.004; 12.04.01.0040.000049%Not Available
Diabetic vascular disorder24.04.03.009; 14.07.05.001; 05.07.05.001--Not Available
Disease progression08.01.03.038--
Drug intolerance08.06.01.013--Not Available
Obstructive airways disorder22.03.01.0110.000121%Not Available
Investigation13.18.01.0040.000121%Not Available
Hyperlipidaemia14.08.03.0010.000049%
Renal impairment20.01.03.010--Not Available
Sinus disorder22.04.06.002--
Unevaluable event08.01.03.0510.000430%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Lichenoid keratosis23.01.01.0040.000049%Not Available
Blood count abnormal13.01.07.0010.000340%Not Available
Chronic kidney disease20.01.03.0170.000340%
Bone marrow failure01.03.03.005--
Iron overload14.13.03.002; 12.02.08.0050.000013%
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.0220.000121%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Head and neck cancer16.16.01.0030.000025%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.000013%Not Available
Acute kidney injury20.01.03.016--
Posterior reversible encephalopathy syndrome17.13.02.0070.000049%
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
The 17th Page    First    Pre   17 18 19    Next   Last    Total 19 Pages